{"id":12423,"date":"2025-04-08T15:15:07","date_gmt":"2025-04-08T13:15:07","guid":{"rendered":"https:\/\/mohnfoundation.no\/?page_id=12423"},"modified":"2025-04-15T12:29:41","modified_gmt":"2025-04-15T10:29:41","slug":"womens-health","status":"publish","type":"page","link":"https:\/\/mohnfoundation.no\/en\/https-mohnfoundation-no-en-thematic-initiatives-womens-health\/womens-health\/","title":{"rendered":"Women\u2019s Health"},"content":{"rendered":"

[vc_row el_class=”article-white” css=”.vc_custom_1699529085046{margin-right: 0px !important;margin-left: 0px !important;}”][vc_column][vc_row_inner][vc_column_inner][\/vc_column_inner][\/vc_row_inner]

Women\u2019s Health<\/h1><\/div>[vc_row_inner][vc_column_inner width=”2\/3″][vc_column_text css=””]Women and men have different biologies and are affected differently by disease. Several illnesses present with different symptoms in women and men, treatments may have different effects depending on sex, and the risk factors contributing to disease onset vary between women and men.<\/p>\n

Although women\u2019s health has received increased attention in recent years, it has for too long held a low status among researchers, educational institutions, and within the healthcare services. This has also been highlighted in the Norwegian Official Report (NOU) 2023:5<\/a><\/u> and forms the basis for the government\u2019s women\u2019s health strategy<\/a><\/u>.<\/p>\n

To address these challenges and promote women\u2019s health, the Trond Mohn Research Foundation, in collaboration with the Faculty of Medicine at the University of Bergen (UiB) and Haukeland University Hospital (Helse Bergen), has invested NOK 50 million in a new research initiative. The Trond Mohn Research Foundation is contributing up to NOK 24 million of this amount.<\/p>\n

The initiative consists of four projects, all affiliated with Driv \u2013 Centre for Wo<\/a>men\u2019s Health Research<\/a> at the University of Bergen:<\/p>\n

\"\"<\/p>\n

Early\u00a0<\/strong>embryonic epimutations and female cancer
\n<\/strong>Principal I<\/em>nvestigator: Stian Knappskog<\/a>, Faculty of Medicine, University of Bergen<\/em><\/p>\n

This project aims to explore how epigenetic changes occurring during fetal development may be a cause of aggressive cancers such as triple-negative breast cancer. A recent breakthrough in the field has shown that 5\u201310% of healthy women have normal cells with epimutations scattered like a \u201cmosaic\u201d throughout the body. This significantly increases the risk of developing triple-negative breast cancer. The project could open new research areas beyond breast cancer, as the results may also be relevant for other cancer types \u2013 and potentially for other women-specific symptoms due to similar epigenetic changes.<\/p>\n

 <\/p>\n

Young women with premature menopause – call for action to improve diagnostics and improve fertility
\n<\/strong>Principal Investigator: Eystein Husebye<\/a>, Faculty of Medicine, University of Bergen<\/em><\/p>\n

Premature menopause and hormonal disturbances\u2014referred to in medical terms as POI (Premature Ovarian Insufficiency)\u2014affect 3% of women under the age of 40. In addition to infertility, consequences include increased risk of cardiovascular disease, osteoporosis, dementia, and autoimmune disorders. Hormone therapy can alleviate menopausal symptoms associated with POI, but no treatment currently exists to restore or improve fertility. The cause remains unknown in most women, and the disease mechanisms are under-researched. This project, through interdisciplinary national and international collaboration, aims to gain unique insights into this condition, uncover sex-specific characteristics of the immune system, and develop new diagnostic tools to help preserve fertility.<\/p>\n

Safe Treatment for Women needing Antiseizure medications – a multimodal translational and epidemiological approach
\n<\/strong>Principal Investigator: Marte-Helene Bj\u00f8rk<\/a>, Faculty of Medicine, University of Bergen<\/em><\/p>\n

The aim of this project is to close knowledge gaps and improve safety for fertile women using antiepileptic drugs. These medications are used to treat epilepsy, bipolar disorder, headaches, pain, and other neurological and psychiatric conditions commonly affecting women. However, if taken during pregnancy, these drugs can lead to congenital malformations and neurodevelopmental disorders. The project is divided into three work packages: evaluating the safety of antiepileptic medications, identifying markers of fetal harm, and validating epigenetic markers in a large multinational cohort.<\/p>\n

Rethinking Ovarian Cancer: Developing Diagnostic and Functional Tools and Designing Innovative Multimodal Treatment Strategies
\n<\/strong>Principal Investigator: Line Bj\u00f8rge<\/a>, Haukeland University Hospital<\/em><\/p>\n

Around 500 women in Norway are diagnosed with ovarian cancer annually, but survival rates are low, and most patients experience relapse. To improve immunotherapy treatment, a better understanding of tumor variation and the suppressive tumor microenvironment is essential. This project aims to enhance our knowledge of the immunobiology of ovarian cancer, develop tools for identifying biomarkers and testing immunotherapies, and establish methods for combining surgery with immunotherapy. The project consists of three components: developing personalized immune profiling tools, modeling tumor interactions to test immunotherapies, and developing a local immunotherapy method using CAR-T cells. Results from preclinical tests will form the basis for a clinical program to be launched by the end of the project period.[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/3″]

FACTS<\/strong><\/p>\n

Early embryonic epimutations and female cancer<\/strong>
\nPrincipal Investigator: Stian Knappskog<\/a><\/em>, UiB, Faculty of Medicine
\nProject Period: 2025\u20132029
\nFunding from TMF: NOK 6 million<\/p>\n

Young women with premature menopause – call for action to improve diagnostics and improve fertility<\/strong>
\nPrincipal Investigator: Eystein Husebye<\/a><\/em>, UiB, Faculty of Medicine
\nProject Period: 2025\u20132029
\nFunding from TMF: NOK 6 million<\/p>\n

Safe Treatment for Women needing Antiseizure medications – a multimodal translational and epidemiological approach<\/strong>
\nPrincipal Investigator: Marte-Helene Bj\u00f8rk<\/a><\/em>, UiB, Faculty of Medicine
\nProject Period: 2025\u20132029
\nFunding from TMF: NOK 6 million<\/p>\n

Rethinking Ovarian Cancer: Developing Diagnostic and Functional Tools and Designing Innovative Multimodal Treatment Strategie<\/strong>
\nPrincipal Investigator: Line Bj\u00f8rge<\/a><\/em>, Haukeland University Hospital
\nProject Period: 2025\u20132028
\nFunding from TMF: NOK 4.5 million<\/p>\n

Image below: From left: Eystein Sverre Husebye, Stian Knappskog, Line Bj\u00f8rge, and Marte Helen Bj\u00f8rk.
\nPhoto\/Illustration: Paul Andre Sommerfeldt, UiB.<\/p><\/div>[vc_single_image image=”12425″ img_size=”full” css=””][vc_single_image image=”12483″ img_size=”full” css=””][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>